Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan D Michelson

Showing results (81-90 of 124) with videos related to

Pageof 13
Sort By:
Clinical Cardiology|May 20, 2008
The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary interventionEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary interventionEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromesEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Investigating the mechanisms of hyporesponse to antiplatelet approachesEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Assessing the current role of platelet function testingEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Blood|February 12, 2005
Platelet activation in cystic fibrosisBrian P O'Sullivan, Matthew D Linden, Andrew L Frelinger, et al.
European Journal of Medicinal Chemistry|November 21, 2015
New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptorsIvan B Yanachkov, Hung Chang, Milka I Yanachkova, et al.
Plos One|September 21, 2011
The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviorsFrank A J L Scheer, Alan D Michelson, Andrew L Frelinger, et al.
Thrombosis and Haemostasis|June 29, 2007
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirinAndrew L Frelinger, Joseph A Jakubowski, Youfu Li, et al.
Thrombosis and Haemostasis|March 25, 2016
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 TrialEdward T Carreras, Willibald Hochholzer, Andrew L Frelinger, et al.
Pageof 13

Showing results (81-90 of 124) with videos related to

Sort By:
Pageof 13
Clinical Cardiology|May 20, 2008
The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary interventionEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary interventionEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromesEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Investigating the mechanisms of hyporesponse to antiplatelet approachesEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Assessing the current role of platelet function testingEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Blood|February 12, 2005
Platelet activation in cystic fibrosisBrian P O'Sullivan, Matthew D Linden, Andrew L Frelinger, et al.
European Journal of Medicinal Chemistry|November 21, 2015
New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptorsIvan B Yanachkov, Hung Chang, Milka I Yanachkova, et al.
Plos One|September 21, 2011
The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviorsFrank A J L Scheer, Alan D Michelson, Andrew L Frelinger, et al.
Thrombosis and Haemostasis|June 29, 2007
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirinAndrew L Frelinger, Joseph A Jakubowski, Youfu Li, et al.
Thrombosis and Haemostasis|March 25, 2016
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 TrialEdward T Carreras, Willibald Hochholzer, Andrew L Frelinger, et al.
Pageof 13